Glutathione injections and IV drips: FDA status, evidence and risks
As of October 15, 2026, there is no FDA-approved glutathione drug, but glutathione sits in Category 1 of FDA’s interim 503A policy, so licensed pharmacies may compound it while FDA evaluates it. That is enforcement discretion, not approval, and it does not show that injections or drips work.
Status at a glance
| Check | Status as of October 15, 2026 | Source · read date |
|---|---|---|
| FDA approval | No FDA-approved glutathione drug product found. | FDA · read October 15, 2026 |
| 503A interim category | Category 1 (“Glutathione”), categories PDF updated May 14, 2026. | FDA · read October 15, 2026; FDA 503A page |
| FDA advisory committee (PCAC) | None found for 2025–2026. | FDA · read October 15, 2026 |
| WADA 2026 Prohibited List | Not named. Method M2.2 prohibits IV infusions over 100 mL per 12 hours outside hospital care. | World Anti-Doping Agency · read October 15, 2026 |
| FDA warning letters, 2026 | None found naming glutathione. | FDA warning letters · read October 15, 2026 |
| WADA 2027 list | Not named on the 2027 list (in force January 1, 2027); the M2.2 limit on IV infusions over 100 mL per 12 hours is unchanged. | World Anti-Doping Agency · read October 15, 2026 |
What glutathione is
Glutathione is a small molecule made of three amino acids (a tripeptide) that the body produces and uses as an antioxidant. Clinics and IV lounges sell it as an injection or drip for “detox”, skin lightening, energy and immune support. Those are marketing claims, not approved uses.
Human evidence
We have not re-read the clinical literature on injected or infused glutathione for this update and cite no trial. In general, the human studies we are aware of are small, and none has led to an FDA approval for any of the uses clinics advertise. A product being in Category 1 tells you nothing about whether it works.
Animal and laboratory evidence
Laboratory research on glutathione’s role in oxidative stress is extensive. Showing that a molecule matters inside cells is not the same as showing that adding more of it by drip improves your health.
Risks
The risks are mainly those of compounded sterile injectables and IV access: contamination, wrong concentration and reactions in a setting not equipped to manage them. Claims of skin lightening are a particular warning sign, because they promise a cosmetic effect no regulator has reviewed. Athletes should note WADA’s 100 mL rule, which applies to the volume, not the contents.
Legal sourcing: who can supply it
Category 1 status means a licensed clinician can prescribe glutathione and a licensed 503A pharmacy can compound it under FDA’s interim policy. Ask the clinic to name that pharmacy. See how to verify a provider and peptide safety.
The lawful route for a prescription peptide in the United States is a licensed clinician who examines you and writes a prescription, filled by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility that is allowed to use that substance. Websites that sell peptides “for research use only” or “not for human consumption” are not a lawful source of medicine for people. On August 24, 2026, FDA sent warning letters to five such sellers — Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides and Tex Peptides — calling their products unapproved new drugs. FDA wrote that the research-use labels did not change its view because the websites showed the products were meant for human use.
October 2026: what changed
- April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
- July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
- October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.
For glutathione: its Category 1 status did not change in 2026. The interim access policy reported on October 15 concerns certain peptides; we have seen nothing suggesting it changes glutathione’s position. Compare NAD+, which is in the same category.
Frequently asked questions
Is glutathione FDA-approved?
No. We found no FDA-approved glutathione drug product as of October 15, 2026. Glutathione is in Category 1 of FDA’s interim 503A policy, which lets licensed pharmacies compound it while FDA evaluates it, but that is not approval.
Can a pharmacy legally compound glutathione?
Yes, under FDA’s interim policy. Category 1 substances may be compounded by licensed 503A pharmacies for individual patients with a prescription, while FDA decides whether to add them to the 503A bulks list.
Does a glutathione drip work for detox or skin lightening?
Those uses are not approved, and we did not find trial evidence strong enough to support them. We have not re-read the literature for this update. Treat promises of detox or lighter skin as marketing.
Does glutathione break anti-doping rules?
Glutathione is not named on WADA’s 2026 list, but method M2.2 prohibits IV infusions or injections over 100 mL in 12 hours outside hospital treatment, surgery or clinical investigations. A large glutathione drip could breach that rule.
Sources
- FDA — Interim policy categories for 503A and 503B bulk drug substances (PDF, updated May 14, 2026) (read October 15, 2026)
- FDA — Bulk drug substances used in compounding under section 503A (page current as of May 14, 2026) (read October 15, 2026)
- World Anti-Doping Agency — Prohibited List (2026 list in force) (read October 15, 2026)
- World Anti-Doping Agency — 2026 Prohibited List (PDF) (read October 15, 2026)
- World Anti-Doping Agency — 2027 Prohibited List (published September 21, 2026; in force January 1, 2027) (read October 15, 2026)